CalciMedica (CALC)

• Market cap: $20.9M
• 1 day: 0.65%
• 5 days: 4.03%
• 1 month: -24.39%
• 3 months: -49.84%
• 6 months: -60.86%
• Year to date: -52.89%
• 1 year: -61.35%
• 5 years: -73.46%
• 10 years: -73.46%
• Sector: Healthcare
• Industry: Biotechnology

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

21% more funds holding

Funds holding: 24 [Q3] → 29 (+5) [Q4]

11% more capital invested

Capital invested by funds: $13.6M [Q3] → $15.1M (+$1.54M) [Q4]

3.14% more ownership

Funds ownership: 28.49% [Q3] → 31.63% (+3.14%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 932% upside
• Avg. target: $16 932% upside
• High target: $16 932% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target

932% upside $16

Buy Reiterated

1 Apr 2025